Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 48

    1.

    Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

    Konstantinopoulos PA, Cannistra SA.

    J Clin Oncol. 2012 Feb 1;30(4):347-50. Epub 2011 Dec 27. No abstract available.

    PMID:
    22203759
    [PubMed - indexed for MEDLINE]
    2.

    Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

    Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B.

    J Clin Oncol. 2012 Feb 1;30(4):372-9. Epub 2011 Dec 27.

    PMID:
    22203755
    [PubMed - indexed for MEDLINE]
    3.

    Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.

    Sood AK, Coleman RL, Ellis LM.

    J Clin Oncol. 2012 Feb 1;30(4):345-7. Epub 2011 Dec 19. No abstract available.

    PMID:
    22184398
    [PubMed - indexed for MEDLINE]
    4.

    Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

    Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB.

    J Clin Oncol. 2012 Feb 1;30(4):362-71. Epub 2011 Dec 19.

    PMID:
    22184370
    [PubMed - indexed for MEDLINE]
    5.

    Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.

    Li HK, Harding V, Williamson R, Blagden S, Gabra H, Agarwal R.

    J Clin Oncol. 2012 Jan 10;30(2):e19-20. Epub 2011 Dec 12. No abstract available.

    PMID:
    22162572
    [PubMed - indexed for MEDLINE]
    6.

    Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

    Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, Domchek S.

    J Clin Oncol. 2011 Nov 10;29(32):4302-6. Epub 2011 Oct 11.

    PMID:
    21990416
    [PubMed - indexed for MEDLINE]
    7.

    Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

    Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

    J Clin Oncol. 2011 Dec 10;29(35):4662-8. Epub 2011 Nov 7.

    PMID:
    22067389
    [PubMed - indexed for MEDLINE]
    8.

    Is the easier way ever the better way?

    Chi DS, Bristow RE, Armstrong DK, Karlan BY.

    J Clin Oncol. 2011 Nov 1;29(31):4073-5. Epub 2011 Sep 19. No abstract available.

    PMID:
    21931018
    [PubMed - indexed for MEDLINE]
    9.

    Malignant transformation of a serous borderline tumor and early metastasis of associated low-grade serous carcinoma detected on screening mammography.

    Rohsbach D, Trillsch F, Regier M, Choschzick M, Kommoss F, Hermsteiner M, Töllner T, Mattner UM, Jaenicke F, Mahner S.

    J Clin Oncol. 2011 Oct 20;29(30):e763-5. Epub 2011 Sep 19. No abstract available.

    PMID:
    21931030
    [PubMed - indexed for MEDLINE]
    10.

    Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.

    Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A.

    J Clin Oncol. 2011 Nov 1;29(31):4076-8. Epub 2011 Sep 19. No abstract available.

    PMID:
    21931032
    [PubMed - indexed for MEDLINE]
    11.

    Preservation of pregnancy in a patient with acute abdominal pain secondary to advanced and hemorrhagic yolk sac tumor of the right ovary.

    Viana LS, Tsunoda AT, Nunes JS, Fregnani JH, Vieira MA, Borges AK, Andrade CE, Serrano SV.

    J Clin Oncol. 2011 Oct 20;29(30):e758-62. Epub 2011 Sep 19. No abstract available.

    PMID:
    21931036
    [PubMed - indexed for MEDLINE]
    12.

    Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.

    Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, Small L, Warren JL.

    J Clin Oncol. 2011 Oct 10;29(29):3921-6. Epub 2011 Sep 12.

    PMID:
    21911719
    [PubMed - indexed for MEDLINE]
    13.

    Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

    Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G.

    J Clin Oncol. 2011 Oct 1;29(28):3798-804. Epub 2011 Aug 22.

    PMID:
    21859991
    [PubMed - indexed for MEDLINE]
    14.

    Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

    Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F.

    J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15.

    PMID:
    21844495
    [PubMed - indexed for MEDLINE]
    15.

    Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

    Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM.

    J Clin Oncol. 2011 Aug 1;29(22):3008-15. Epub 2011 Jun 27.

    PMID:
    21709188
    [PubMed - indexed for MEDLINE]
    16.

    Multiple osteolytic bone lesions 3 years after ovarian cancer: benign or malignant?

    Guo JJ, Liu W, Yang H, Qian H, Tang T, Qin L.

    J Clin Oncol. 2011 Aug 10;29(23):e672-4. Epub 2011 Jun 13. No abstract available.

    PMID:
    21670446
    [PubMed - indexed for MEDLINE]
    17.

    Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication.

    Khan MI, Waguespack SG, Habra MA, Broaddus R, Jimenez C.

    J Clin Oncol. 2011 Jun 1;29(16):e462-4. Epub 2011 Mar 21. No abstract available.

    PMID:
    21422435
    [PubMed - indexed for MEDLINE]
    18.

    Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

    Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, de Fazio A, Fereday S, Bowtell DD, Green AC, Webb PM.

    J Clin Oncol. 2011 Jun 1;29(16):2253-8. Epub 2011 May 2.

    PMID:
    21537035
    [PubMed - indexed for MEDLINE]
    19.

    Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?

    Bach PB, Vickers AJ.

    J Clin Oncol. 2011 May 1;29(13):e387; author reply e388-9. Epub 2011 Mar 21. No abstract available.

    PMID:
    21422419
    [PubMed - indexed for MEDLINE]
    20.

    Hepatoid carcinoma of the ovary.

    Pandey M, Truica C.

    J Clin Oncol. 2011 May 20;29(15):e446-8. Epub 2011 Mar 21. No abstract available.

    PMID:
    21422440
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk